Overview
- 19 FDA inspections are on record.
- 6 inspections produced a Form 483.
- The most recent recorded inspection date is 2025-09-11.
At a glance
Inspections
19
Form 483s
6
EIRs
2
Last outcome
Form 483
Inspection history
FDA inspections on record, most recent first.
| Inspection | Category | Outcome | Form 483 |
|---|---|---|---|
| 4 Sep 2025 – 11 Sep 2025 | Human Drugs | 483 | View 483 → |
| 29 Apr 2024 – 2 May 2024 | Biologics | Clean | |
| 19 Sep 2023 – 22 Sep 2023 | Human Drugs | Clean | |
| 9 Dec 2019 – 12 Dec 2019 | Human Drugs | 483 | View 483 → |
| 12 Nov 2018 – 6 Dec 2018 | Human Drugs | 483 | View 483 → |
| 17 Jul 2017 – 28 Jul 2017 | Human Drugs | 483 | View 483 → |
| 22 Feb 2016 – 26 Feb 2016 | Human Drugs | Clean | |
| 14 Jul 2014 – 24 Jul 2014 | Human Drugs | Clean | |
| 4 Dec 2013 – 18 Dec 2013 | Human Drugs | Clean | |
| 25 Mar 2013 – 28 Mar 2013 | Human Drugs | Clean | |
| 30 Jan 2013 | Not recorded | 483 | View 483 → |
| 3 Dec 2012 | Not recorded | Clean | |
Observations on record
Form 483 observations cited at this site, most recent first.
12 Dec 2019
21 CFR 312.50
Ensuring compliance with plan and protocol
Cited by Peter R Lenahan, Cynthia F Kleppinger, Miah Jung
12 Dec 2019
21 CFR 312.56(b)
Notification of FDA of termination of investigator
Cited by Peter R Lenahan, Cynthia F Kleppinger, Miah Jung
12 Dec 2019
21 CFR 312.57(c)
Record retention requirement
Cited by Peter R Lenahan, Cynthia F Kleppinger, Miah Jung
Investigators
FDA investigators tied to this site in the record.
M. P Murphy6 insp.
Matthew C Watson2 insp.
Maya M Davis2 insp.
Kent A Conforti1 insp.
Deborah A Greco1 insp.
Peter R Lenahan1 insp.
Cynthia F Kleppinger1 insp.
Miah Jung1 insp.
Victoria M Daddeo1 insp.
Christopher Janik1 insp.
Susanne M Richardson1 insp.
Mark R Mcclain1 insp.
Janete F Guardia1 insp.
Michelle M Noe1 insp.
Diane C Thibodeau1 insp.
Recurring citations
CFR citation patterns observed across this site's inspections.
| Citation | What it covers | Cited |
|---|---|---|
| 21 CFR 312.50 | Cited across public-safe Form 483 observations | 4x |
| 21 CFR 314.80(b) | Cited across public-safe Form 483 observations | 2x |
| 21 CFR 211.25(a) | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 312.120(c) | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 312.52(a) | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 312.56(b) | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 312.57(c) | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 314.80(c)(1)(i) | Cited across public-safe Form 483 observations | 1x |
Full site report
Get the verbatim findings behind Boehringer Ingelheim Pharmaceuticals, Inc.'s 6 Form 483s
Source PDFs, verbatim observations, and recurring CFR citations, so your team knows what this site gets cited for.
- The site's full inspection history, with every Form 483 and its outcome
- Warning letters and recalls tied to the company behind it
- Whether recurring CFR citations get closed out or repeat